EVA MARÍA
CIRUELOS GIL
Profesora asociada de Ciencias de la Salud
KU Leuven
Lovaina, BélgicaPublicaciones en colaboración con investigadores/as de KU Leuven (9)
2023
-
Genomic characterisation of hormone receptor-positive breast cancer arising in very young women
Annals of Oncology, Vol. 34, Núm. 4, pp. 397-409
2021
-
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
The Lancet Oncology, Vol. 22, Núm. 4, pp. 489-498
-
Expected medium- And long-term impact of the COVID-19 outbreak in oncology
JCO Global Oncology, Vol. 7, pp. 162-172
-
Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in Aurora, the breast international group (Big) molecular screening initiative
Cancer Discovery, Vol. 11, Núm. 11, pp. 2796-2811
2020
-
Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population
Clinical and Translational Oncology, Vol. 22, Núm. 10, pp. 1857-1866
2019
-
Survival outcomes of the NeoALTTO study (BIG 1–06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer
European Journal of Cancer, Vol. 118, pp. 169-177
2018
-
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
The Lancet Oncology, Vol. 19, Núm. 1, pp. 127-138
2016
-
Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: Patient-reported outcomes in the suppression of ovarian function trial
Journal of Clinical Oncology, Vol. 34, Núm. 14, pp. 1601-1610
-
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: Primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)
Annals of Oncology, Vol. 27, Núm. 9, pp. 1719-1725